Fortrea Holdings Inc. (FTRE) Financial Ratio Screen
Track FTRE screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
FTRE financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Biotechnology) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: Not yet checked against an SEC annual filing.
Profile description reviewed: Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 41.1% / 30% | 6.4% / 30% | 29.3% / 30% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
| FTSE | 41.1% / 33% | 6.4% / 33% | 29.3% / 50% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
Financial Highlights
Profitability
| Gross Margin | 18.5% | |
| Operating Margin | 1.3% | |
| Net Margin | -36.2% | |
| Return on Equity (ROE) | -102.4% | |
| Return on Assets (ROA) | -0.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $114M |
| Free Cash Flow | $88M |
| Total Debt | $1.1B |
| Debt-to-Equity | 198.3 |
| Current Ratio | 1.0 |
| Total Assets | $2.7B |
Price & Trading
| Last Close | $9.55 |
| 50-Day MA | $12.20 |
| 200-Day MA | $10.58 |
| Avg Volume | 1.7M |
| Beta | 1.8 |
|
52-Week Range
$3.97
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-03-29 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About Fortrea Holdings Inc. (FTRE)
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is Fortrea Holdings Inc. (FTRE) halal to invest in?
The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is Fortrea Holdings Inc.'s debt ratio?
Fortrea Holdings Inc.'s debt ratio is 41.1% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are Fortrea Holdings Inc.'s key financial metrics?
Fortrea Holdings Inc. has a market capitalization of USD 848M in its listing currency, and revenue of $2.7B. The company maintains a gross margin of 18.5% and a net margin of -36.2%. Return on equity stands at -102.4%.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.